De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Amneal Pharmaceuticals Beheer
Beheer criteriumcontroles 4/4
De CEO Amneal Pharmaceuticals' is Chirag Patel, benoemd in Jan2005, heeft een ambtstermijn van 19.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.37M, bestaande uit 31.6% salaris en 68.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 7.04% van de aandelen van het bedrijf, ter waarde $ 181.23M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 6.4 jaar.
Belangrijke informatie
Chirag Patel
Algemeen directeur
US$2.4m
Totale compensatie
| Percentage CEO-salaris | 31.6% |
| Dienstverband CEO | 19.8yrs |
| Eigendom CEO | 7.0% |
| Management gemiddelde ambtstermijn | 5.3yrs |
| Gemiddelde ambtstermijn bestuur | 6.4yrs |
Recente managementupdates
Recent updates
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
Jul 10Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Apr 15
Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?
Mar 19Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry
Dec 28Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
Dec 10Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Nov 28Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt
Sep 24Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Aug 08Amneal Pharmaceuticals Could Have An Upbeat Q2
Jul 10These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively
Apr 18Amneal Pharmaceuticals: Risk Still Persists
Jan 23Amneal Pharma reaffirms 2022 guidance
Jan 10Amneal joins hands with Orion to commercialize generic products in Europe and more countries
Jan 04Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load
Dec 20Amneal Pharmaceuticals large shareholder TPG cuts stake
Dec 14FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203
Nov 11Amneal Pharmaceuticals Q3 2022 Earnings Preview
Nov 03Amneal Pharmaceuticals: A Small 'Thumbs Up'
Oct 28Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet
Sep 01Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment
Aug 31Amneal Pharmaceuticals Q2 2022 Earnings Preview
Aug 04Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$2m | US$750k | -US$84m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$5m | US$750k | -US$130m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | US$2m |
| Dec 31 2021 | US$5m | US$724k | US$11m |
| Sep 30 2021 | n/a | n/a | US$14m |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$2m | US$1 | US$91m |
| Sep 30 2020 | n/a | n/a | US$62m |
| Jun 30 2020 | n/a | n/a | -US$194m |
| Mar 31 2020 | n/a | n/a | -US$199m |
| Dec 31 2019 | US$446k | US$44k | -US$362m |
| Sep 30 2019 | n/a | n/a | -US$339m |
| Jun 30 2019 | n/a | n/a | -US$67m |
| Mar 31 2019 | n/a | n/a | -US$69m |
| Dec 31 2018 | US$325k | n/a | -US$21m |
Compensatie versus markt: De totale vergoeding ($USD 2.37M ) Chirag } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).
Compensatie versus inkomsten: De vergoeding van Chirag is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Chirag Patel (57 yo)
19.8yrs
Tenure
US$2,370,385
Compensatie
Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 19.8yrs | US$2.37m | 7.04% $ 188.4m | |
| Co-Founder | 22.8yrs | US$2.37m | 8.16% $ 218.5m | |
| Executive VP & CFO | 4.6yrs | US$1.89m | 0.17% $ 4.6m | |
| Senior VP | 2.8yrs | US$1.35m | 0.019% $ 495.9k | |
| Executive VP & Chief Human Resources Officer | 10.8yrs | US$1.53m | 0.094% $ 2.5m | |
| Executive VP & Chief Commercial Officer of Generics | 6.7yrs | US$1.94m | 0.083% $ 2.2m | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Corporate Development | 1.8yrs | geen gegevens | geen gegevens | |
| Senior VP of Strategic Sourcing & Supply Management | 1.8yrs | geen gegevens | geen gegevens | |
| Chief Quality Officer | 5.8yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Scientific Officer of Generics | 4.8yrs | geen gegevens | geen gegevens | |
| Vice President & Head of Medical Affairs | no data | geen gegevens | geen gegevens |
5.3yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AMRX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 19.8yrs | US$2.37m | 7.04% $ 188.4m | |
| Co-Founder | 22.8yrs | US$2.37m | 8.16% $ 218.5m | |
| Independent Chairman of the Board | 5.2yrs | US$299.08k | 0.24% $ 6.3m | |
| Independent Director | 6.4yrs | US$302.20k | 0.085% $ 2.3m | |
| Independent Director | 6.4yrs | US$244.70k | 0.097% $ 2.6m | |
| Independent Director | 4.8yrs | US$254.70k | 0.079% $ 2.1m | |
| Independent Director | 4.8yrs | US$277.20k | 0.087% $ 2.3m | |
| Director | 6.4yrs | US$217.20k | 0.66% $ 17.7m | |
| Independent Director | 2.3yrs | US$267.04k | 0.030% $ 807.8k | |
| Independent Director | 6.4yrs | US$217.20k | 0.081% $ 2.2m | |
| Independent Director | 4.8yrs | US$284.70k | 0.083% $ 2.2m |
6.4yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AMRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.4 jaar).